REGENXBIO Faces Securities Class Action Over RGX-111 Gene Therapy Claims
Securities lawsuit alleges REGENXBIO made misleading statements about RGX-111 gene therapy. Investors have until April 14, 2026 to file.
RGNXsecurities class actionlead plaintiff deadline